Neurology, Oncology & Neurodegeneration
Cancer, Parkinson's disease, dementia, and epilepsy carry the heaviest burden of the conditions we study. Our neurology, oncology, and neurodegeneration programs run side by side so that discoveries in one area can be tested quickly in the others. Agave Biomedical was founded in 2026, and these interconnected areas define where our early work is concentrated.
Tumor biology and resistance
We study how cancer cells evade treatment, mapping the pathways that drive resistance so combination therapies can be designed around them rather than against them.
Neurodegeneration mechanisms
Parkinson's disease and dementia share protein-misfolding and neuroinflammatory features. We investigate those shared mechanisms to find interventions that slow progression.
Neurology and epilepsy
Epilepsy and related neurological conditions involve disrupted neural circuits. We explore how targeted modulation, biomarker-guided dosing, and gene therapy approaches can reduce seizure burden and improve quality of life.
Cross-research gene therapy
Gene-directed approaches are our core focus. Insights that emerge in oncology models frequently inform our neurodegeneration and neurology work, and the reverse is just as true.
How this connects to our other work
Neurology, oncology, and neurodegeneration are where our other research areas converge. Candidate molecules come out of drug discovery, targets are prioritized through genomics, earlier detection depends on diagnostics and biomarkers, and access is shaped by our public health work.